Head-to-head · free
Vera Therapeutics, Inc. vs Xenon Pharmaceuticals Inc.
VERA vs XENE — return on capital, cash generation, margins and balance sheet side by side.
VERA
3 / 4
measures where VERA leads
XENE
1 / 4
measures where XENE leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | VERA · FY2025 | XENE · FY2025 |
|---|---|---|
| Revenue | — | — |
| Net income | (299.6M) | (345.9M) |
| Revenue growth (yearly, multi-year) | — | — |
| Free cash flow | (241.7M) | (279.9M) |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -50.7% | -51.8% |
| Gross margin | — | — |
| Operating margin | — | -4974.3% |
| Net debt / EBITDA | 0.89x | 0.54x |
Figures are as reported by each company; latest fiscal year shown.
Where Vera Therapeutics, Inc.'s cash went (FY2025)
- Capital spending
- $630000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Xenon Pharmaceuticals Inc.'s cash went (FY2025)
- Capital spending
- $799000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free